Standard Motor Products (SMP) manufactures and distributes replacement parts for motor vehicles in the automotive aftermarket industry.
The company's Engine Management segment manufactures and sells engine management replacement parts, including electronic ignition control modules, fuel injectors, ignition wires, voltage regulators, coils, switches, emission sensors, EGR valves, distributor caps and rotors, and other engine management components primarily under the Standard, BWD, Intermotor, OEM, TechSmart, and GP Sorensen brand names. This segment also manufactures fuel pressure regulators, air by-pass valves, idle air control valves, and PCV valves; spark plug wires and battery cables; and various electrical wires, terminals, connectors, and tools for servicing an automobiles electrical system, as well as distributes a range of engine management products, including ignition coils, ignition modules, switches and sensors, and filters.
Its Temperature Control segment manufactures, remanufactures, and markets various replacement parts for automotive temperature control systems, engine cooling systems, power window accessories, and windshield washer systems primarily under the Four Seasons, EVERCO, ACi, Hayden, Factory Air, and Imperial brand names. This segment also provides remanufactured compressors, clutch assemblies, blower and radiator fan motors, filter dryers, evaporators, accumulators, hose assemblies, expansion valves, heater valves, AC service tools and chemicals, fan assemblies, fan clutches, engine oil coolers, transmission coolers, window lift motors, motor/regulator assemblies, and windshield washer pumps.
The company sells its products to warehouse distributors, large retail chains, original equipment manufacturers, and original equipment service part operators in the United States, Canada, Europe, Asia, and Latin America.
SMP Investor Highlights
Earnings from continuing operations for the third quarter of 2012 were $17.4 million or 76 cents per diluted share, compared to $14.1 million or 61 cents per diluted share in the third quarter of 2011.
Consolidated net sales for the third quarter of 2012 were $276 million, compared to consolidated net sales of $236.2 million during the comparable quarter in 2011.
The Board of Directors has approved payment of a quarterly dividend of nine cents per share on the common stock outstanding. The dividend will be paid on December 3, 2012 to stockholders of record on November 15, 2012.
StemCells (STEM) a biopharmaceutical company, engages in the research, development, and commercialization of stem cell therapeutics, and related tools and technologies for academia and industry.
It develops cell-based therapeutics for the central nervous system and liver. The company's product candidate HuCNS-SC cells has completed a Phase I clinical trial for the treatment of infantile and late infantile neuronal ceroid lipofuscinosis, a neurodegenerative disorder of the brain; and completed a Phase I clinical trial for the treatment of Pelizeaus-Merzbacher disease, a fatal myelination disorder in the brain. It also engages in developing HuCNS-SC cells, which are in Phase I/II clinical trial for the treatment of chronic spinal cord injury; and HuCNS-SC cells that are in Phase I/II clinical trial for the treatment of dry age-related macular degeneration.
In addition, the company identifies and develops human liver engrafting cells for a range of liver diseases; and is involved in developing and commercializing applications of its technologies to enable stem cell-based research. Further, it markets a range of proprietary cell culture products under the SC Proven brand, including iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff N2B27, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents under the SC Proven brand comprising STEM24, STEM101, STEM121, and STEM123 for cell detection, isolation, and characterization. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories.
STEM Investor Highlights
Partnered with R Biomedical, an Edinburgh, UK-based biomedical company, to develop and commercialize a range of cell lines and reagents to facilitate human induced pluripotent stem (iPS) cell-based research for regenerative medicine applications. The first product under the partnership, an "ultra-primary" human fibroblast cell line from which researchers can generate iPS cell lines, was launched today under the SC Proven brand.
StemCells has a broad and expanding clinical development program for its HuCNS-SC cells. The Company has ongoing Phase I/II clinical trials in chronic thoracic spinal cord injury and dry age-related macular degeneration, and is planning for a controlled Phase II study in Pelizaeus-Merzbacher Disease.
Announced the issuance of U.S. Patent Number 8,283, 164 titled "Liver engrafting cells, assays, and uses thereof." The patent broadly covers purified populations of human liver cells, including the Company's human liver engrafting cells (hLEC). hLEC cells were first isolated by Company researchers in the late 1990s, and Company scientists have repeatedly demonstrated the cells' engraftment and robust bioactivity in vivo and that they are expandable.
In October 2011, StemCells formed a wholly-owned subsidiary to focus on both the therapeutic and research tool applications of its hLEC technologies and to serve as an investment vehicle for those interested in a "pure play" liver cell company.
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has not been compensated by any of the above mentioned companies.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit SmallCapReview.com/.